B
B

Biogen

News

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Adds background Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid bet
B

EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen Adds background Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid bet
B

EU regulator accepts Biogen-Eisai's Alzheimer's treatment lecanemab for review

EU regulator accepts Biogen-Eisai's Alzheimer's treatment lecanemab for review Jan 26 (Reuters) - Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug for review. The drug, lecanemab, was recently granted accelerated approval in the United States.
B

Lonza to buy back $2.17 bln worth of shares, backs mid-term growth

UPDATE 2-Lonza to buy back $2.17 bln worth of shares, backs mid-term growth Adds background on investments, headwinds By Ludwig Burger and Tristan Chabba Jan 25 (Reuters) - Lonza LONN.S on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future.
B
L

Lonza full-year earnings edge market expectations

Lonza full-year earnings edge market expectations Jan 25 (Reuters) - Swiss drug contract manufacturer Lonza LONN.S reported full-year core earnings above expectations, as demand from biopharmaceutical companies remained strong throughout the year. The Basel-based firm reported core EBITDA, or earnings before interest, taxes, depreciation, amortisation and special items, of 2.0 billion Swiss francs ($2.17 billion), up 19.8%.
B
L

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.